LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Holdings Increased by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 45.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 147,489 shares of the medical instruments supplier's stock after buying an additional 46,430 shares during the period. JPMorgan Chase & Co. owned 0.66% of LeMaitre Vascular worth $13,590,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Copeland Capital Management LLC increased its stake in LeMaitre Vascular by 0.7% during the fourth quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier's stock worth $107,990,000 after acquiring an additional 8,623 shares during the last quarter. State Street Corp boosted its stake in LeMaitre Vascular by 3.6% during the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock valued at $76,363,000 after acquiring an additional 28,525 shares during the last quarter. Congress Asset Management Co. lifted its position in shares of LeMaitre Vascular by 1.8% during the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock worth $66,555,000 after purchasing an additional 13,009 shares during the last quarter. Geode Capital Management LLC lifted its holdings in LeMaitre Vascular by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier's stock worth $50,403,000 after buying an additional 23,443 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in LeMaitre Vascular by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 195,752 shares of the medical instruments supplier's stock worth $18,037,000 after purchasing an additional 4,241 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

Insider Buying and Selling at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This represents a 26.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Trading Up 0.8 %

LMAT stock traded up $0.67 on Thursday, hitting $85.34. 28,251 shares of the company's stock traded hands, compared to its average volume of 210,907. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 46.64, a P/E/G ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58. The stock has a fifty day moving average of $88.31 and a 200-day moving average of $93.56.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts' consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.94%. The ex-dividend date of this dividend was Thursday, March 13th. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's payout ratio is presently 41.24%.

Wall Street Analyst Weigh In

LMAT has been the subject of several recent research reports. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target for the company. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, Lake Street Capital increased their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $95.25.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.